Advanced search
Publication Cover
Journal of Medical Economics Volume 24, 2021 - Issue 1
Submit an article Journal homepage
2,820
Views
2
CrossRef citations to date
0
Altmetric
Oncology

The cost-effectiveness of dacomitinib in first-line treatment of advanced/metastatic epidermal growth factor receptor mutation-positive non-small-cell lung cancer (EGFRm NSCLC) in Sweden

Fredrik O. L. Nilssona Health and Value Sweden, Pfizer Innovations AB, Stockholm, SwedenCorrespondence[email protected]
,
Peter Galb Evidence Synthesis, Modeling & Communication, Evidera, Budapest, Hungary
,
Ivan Houisseb Evidence Synthesis, Modeling & Communication, Evidera, Budapest, Hungary
,
Jasmina I. Ivanovac Global Health Economics and Outcomes Research (Oncology), Pfizer Inc, New York, NY, USA
&
Sandra T. Asanind Oncology Sweden, Pfizer Innovations AB, Stockholm, Sweden
Pages 447-457 | Received 02 Oct 2020, Accepted 25 Feb 2021, Published online: 09 Apr 2021

Reprints and Permissions

Permission is granted subject to the terms of the License under which the work was published. Permission will be required if your reuse is not covered by the terms of the License.

To request a reprint or commercial or derivative permissions for this article, please click on the relevant link below.

Order Reprints Request Permissions

For more information please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.